These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 746249)

  • 61. Current results of a multicenter trial in multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Deicher H; Boll J; Essers U; Gamm H; Glück S; Görg K; Gramatzki M
    Onkologie; 1986 Jun; 9(3):168-9. PubMed ID: 3528964
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
    Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
    N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
    J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
    Minarik J; Sandecka V; Maisnar V; Gregora E; Spicka I; Starostka D; Plonkova H; Jarkovsky J; Walterova L; Wrobel M; Adamova D; Pika T; Melicharova H; Pour L; Radocha J; Pavlicek P; Straub J; Gumulec J; Bacovsky J; Adam Z; Scudla V; Hajek R
    Leuk Res; 2013 Sep; 37(9):1063-9. PubMed ID: 23845888
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
    Cohen HJ; Bartolucci AA; Forman WB; Silberman HR
    J Clin Oncol; 1986 Jun; 4(6):888-99. PubMed ID: 3519879
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
    Shimizu K; Kamiya O; Hirabayashi N; Ichikawa A; Kawashima K; Kobayashi M; Mizuno H; Nagura E; Nitta M; Saito H; Sao H; Shibata T; Takeyama H
    Jpn J Cancer Res; 1999 Mar; 90(3):355-60. PubMed ID: 10359052
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
    Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
    Pönisch W; Mitrou PS; Merkle K; Herold M; Assmann M; Wilhelm G; Dachselt K; Richter P; Schirmer V; Schulze A; Subert R; Harksel B; Grobe N; Stelzer E; Schulze M; Bittrich A; Freund M; Pasold R; Friedrich T; Helbig W; Niederwieser D;
    J Cancer Res Clin Oncol; 2006 Apr; 132(4):205-12. PubMed ID: 16402269
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current concepts in cancer. Multiple myeloma.
    McIntyre OR
    N Engl J Med; 1979 Jul; 301(4):193-6. PubMed ID: 377077
    [No Abstract]   [Full Text] [Related]  

  • 78. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
    Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
    J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
    Bettini R; Tonolini M; Bernasconi M
    Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.